

Special Issue

Gene Therapy in Cardiovascular Genetics

Message from the Guest Editors

Genetic research in the cardiovascular field has come a long way and has brought critical knowledge about the molecular basis and mechanisms of diseases such as cardiomyopathy arrhythmias and skeletal myopathies/dystrophies with cardiac involvement. This wealth of information has led to the development of novel therapeutic interventions, which are tailored for specific molecular changes, such as variants in the LMNA, MYBPC3, TTN, and GLA genes, among others (<https://www.clinicaltrials.gov/search?cond=Cardiomyopathy&intr=gene%20therapy>), thus

making specific genetic information both a diagnostic tool and a pre-requisite to enter ongoing clinical trials or be the recipient of approved gene therapy. In this issue, we will explore how genetic information has shaped the current clinical landscape, modifying patient management and leading to more customized interventions such as gene and targeted drug therapies.

Guest Editors

Dr. Matteo Vatta

Department of Medical and Molecular Genetics, Indiana University
School of Medicine, Indianapolis, IN 46202, USA

Dr. Valeria Novelli

Centro Cardiologico Monzino, Milan, Italy

Deadline for manuscript submissions

30 April 2026



Cardiogenetics

an Open Access Journal
by MDPI

Impact Factor 0.9
CiteScore 1.4



mdpi.com/si/208960

Cardiogenetics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cardiogenetics@mdpi.com

[mdpi.com/journal/
cardiogenetics](https://mdpi.com/journal/cardiogenetics)





Cardigenetics

an Open Access Journal
by MDPI

Impact Factor 0.9
CiteScore 1.4



[mdpi.com/journal/
cardigenetics](https://mdpi.com/journal/cardigenetics)



About the Journal

Message from the Editor-in-Chief

Cardigenetics is an essential resource for general physicians, cardiologists, and geneticists. Exome sequencing, noncoding DNA, bioinformatics, micro-RNA, long-noncoding DNA and epigenetics have entered our daily vocabulary, highlighting the importance of forming a “cardigenetics team” working side by side, bringing the lab to the patients’ bed, and vice versa. A strong Editorial Board of active clinicians and scientists will support this new experience. *Cardigenetics* publishes high-quality original research papers, review articles, short reports, news and views, with the aim of connecting the scientific (bench) to the clinical (bedside) world. Since 2011, the journal has been increasingly successful. Please help us to overcome this challenge.

Editor-in-Chief

Dr. Giuseppe Limongelli

Department of Translational Medical Sciences, Inherited and Rare Heart Disease, Vanvitelli Cardiology, University of Campania Luigi Vanvitelli, 80131 Naples, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, Embase, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 32.1 days after submission; acceptance to publication is undertaken in 9.2 days (median values for papers published in this journal in the first half of 2025).